The companies collaborated to evaluate the safety, tolerability, PK, PD & preliminary antitumor activity of OTX-2002 as monotx. & in combination with Roche’s atezolizumab in the P-I/II trial (MYCHELANGELO I) for MYC-driven HCC & other solid tumor types
Roche will be responsible to supply atezolizumab and Omega will evaluate the combination as part of the overall conduct of the trial
Anti-PD-1 & anti-PD-L1 immune checkpoint inhibitors which are used as SoC treatments for HCC showed synergistic antitumor activity with OTX-2002 in preclinical studies with minimal impact on safety & tolerability. The preliminary results from the monotx. dose escalation portion of the study is expected in 2023
Ref: Omega | Image: Omega
Related News:- Confo Therapeutics Entered into a Collaboration Agreement with Daiichi Sankyo to Discover Novel Therapies for Central Nervous System Disease
